-
EP3736333
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3736333
| EP3736333 - ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.05.2021 Database last updated on 16.11.2024 | |
| Former | The application has been published Status updated on 09.10.2020 | Most recent event Tooltip | 29.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Arrowhead Pharmaceuticals, Inc. 177 E. Colorado Boulevard, Suite 700 Pasadena, CA 91105 / US | [2020/46] | Inventor(s) | 01 /
BETTENCOURT, Brian RaNA Therapeutics, Inc. 200 Sidney Street Suite 301 Cambridge, MA 02139 / US | 02 /
MILSTEIN, Stuart Alnylam Pharmaceuticals Inc. 300 Third Street Cambridge, MA 02142 / US | 03 /
TOUDJARSKA, Ivanka Alnylam Pharmaceuticals Inc. 300 Third Street Cambridge, MA 02142 / US | 04 /
MCDONALD, Earl Novartis Institutes for BioMedical 250 Massachusetts Avenue Cambridge, MA 02139 / US | 05 /
SCHLABACH, Michael Jr. KSQ Therapeutics 790 Memorial Drive, N 200 Cambridge, MA 02139 / US | 06 /
STEIGMEIER, Frank P. KSQ Therapeutics 790 Memorial Drive, 200 Cambridge, MA 02139 / US | 07 /
WARMUTH, Markus H3 Biomedicine, Inc. 300 Technology Square, N5 Cambridge, MA 02139 / US | 08 /
GAMPA, Kalyani Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | 09 /
HUESKEN, Dieter Novartis Pharma AG Postfach 4006 Basel / CH | 10 /
STUMP, Mark Cell Signaling Technology 3 Trask Lane Danvers, MA 01923 / US | 11 /
WEILER, Jan Novartis Institutes for BioMedical 250 Massachusettrs Avenue Cambridge, MA 02139 / US | 12 /
JAGANI, Zainab Novartis Institutes for BioMedical 250 Massachusettrs Avenue Cambridge, MA 02139 / US | [2020/46] | Representative(s) | Arnold & Siedsma Bezuidenhoutseweg 57 2594 AC The Hague / NL | [2020/46] | Application number, filing date | 20178501.1 | 30.04.2013 | [2020/46] | Priority number, date | US201261641588P | 02.05.2012 Original published format: US 201261641588 P | [2020/46] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3736333 | Date: | 11.11.2020 | Language: | EN | [2020/46] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.10.2020 | Classification | IPC: | C12N15/113, A61P35/00, A61K31/713 | [2020/46] | CPC: |
A61K31/713 (EP,US);
A61K45/06 (EP,US);
A61K47/549 (US);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
C12N15/113 (US);
C12N15/1135 (EP,US);
C12N2310/14 (EP,US);
| C-Set: |
C12N2310/344, C12N2310/321, C12N2310/3521 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/24] |
| Former [2020/46] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | ORGANISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KRAS-BEDINGTEN ERKRANKUNGEN | [2020/46] | English: | ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES | [2020/46] | French: | COMPOSITIONS ORGANIQUES POUR TRAITER DES MALADIES ASSOCIÉES À KRAS | [2020/46] | Examination procedure | 10.05.2021 | Examination requested [2021/24] | 10.05.2021 | Date on which the examining division has become responsible | 04.06.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 27.07.2021 | Amendment by applicant (claims and/or description) | Parent application(s) Tooltip | EP13721578.6 / EP2844757 | EP17187348.2 / EP3272868 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 27.07.2021 | Request for further processing filed | 27.07.2021 | Full payment received (date of receipt of payment) Request granted | 11.08.2021 | Decision despatched | Fees paid | Renewal fee | 05.06.2020 | Renewal fee patent year 03 | 05.06.2020 | Renewal fee patent year 04 | 05.06.2020 | Renewal fee patent year 05 | 05.06.2020 | Renewal fee patent year 06 | 05.06.2020 | Renewal fee patent year 07 | 05.06.2020 | Renewal fee patent year 08 | 27.04.2021 | Renewal fee patent year 09 | 31.03.2022 | Renewal fee patent year 10 | 27.04.2023 | Renewal fee patent year 11 | 29.04.2024 | Renewal fee patent year 12 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2005040379 (SIRNA THERAPEUTICS INC [US], et al); | [A]WO2008109516 (MDRNA INC [US], et al); | [XAI]WO2009108217 (INTRADIGM CORP [US], et al); | [A]WO2010115202 (DICERNA PHARMACEUTICALS INC [US], et al); | [A]WO2010115206 (DICERNA PHARMACEUTICALS INC [US], et al); | [A]WO2011110671 (MAX PLANCK GESELLSCHAFT [DE], et al); | by applicant | US5030453 | US5962016 | WO0044914 | CA2359180 | WO0168836 | WO02100435 | US2003012812 | WO03015757 | WO2004002453 | US6680068 | WO2004029213 | US2004204377 | US2004208921 | WO2005021749 | US2006240093 | US2007135372 | WO2007107162 | WO2007128477 | WO2008147824 | WO2009082817 | US2009209626 | WO2011076807 |